시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 트랜스티레틴 아밀로이드 심근증(ATTR-CM) 치료 시장 보고서(2025년)
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Global Market Report 2025
상품코드 : 1720911
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,301,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,108,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,914,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

트랜스티레틴 아밀로이드 심근증(ATTR-CM) 치료 시장 규모는 향후 수년간 비약적인 성장이 예상될 예정입니다. 트랜스티레틴 아밀로이드증의 유병률 증가, 신경병증성 질환 진단 증가, 고령화 인구 증가, 이 드문 장애의 증상을 치료하기 위한 특이적인 약제에 대한 수요 증가, 헬스케어 수요의 전체적인 증가에 기인한다고 생각됩니다. 이 기간의 주요 동향으로서는 새로운 진단 기술의 개발, 치료 관리를 위한 혁신적 기술, 트랜스사이레틴 아밀로이드시스의 표적 치료, 진단 방법의 발전 그리고 심장 MRI 기술의 개선을 포함합니다.

만성 질환의 유병률 증가는 향후 트랜스티레틴 아밀로이드 심근증(ATTR-CM) 치료 시장의 성장을 이끌 것으로 예측됩니다. 인구의 고령화, 좌식 생활 방식, 건강에 해로운 식생활, 비만률의 상승, 환경 오염물질에의 노출 등의 요인에 의한 것입니다. 예를 들어, 2023년 9월 세계보건기구(WHO)는 비전염성 질환(NCDs) 또는 만성질환으로 인해 연간 4,100만 명이 사망하여 세계 사망자 수의 74%를 차지하고 있다고 보고했습니다. 그 내역은 심혈관질환이 1,790만명, 암이 930만명, 만성호흡기질환이 410만명, 당뇨병이 200만명으로 되어 있습니다.

트랜스티레틴 아밀로이드 심근증(ATTR-CM) 치료 시장의 기업은 트랜스사이레틴(TTR) 단백질을 표적으로 하여 안정화하거나 심장의 아밀로이드 섬유의 축적을 억제하는 경구약 등 혁신 치료법의 개발에도 주력하고 있습니다. 경구 처방약이란, 의료 종사자의 처방에 따라, 통상 정제, 캡슐제, 액제 등의 형태로 입으로부터 복용하는 약제를 말합니다. 2024년 11월, 미국에 본사를 둔 생명공학 회사 브리지 바이오 파마사는 트랜스티레틴 아밀로이드 심근증(ATTR-CM) 치료의 성인에 대한 경구 치료제인 아토르비(아코라미디스)의 승인을 미국 식품의약국(FDA)으로부터 받았습니다. 이 약은 TTR 단백질을 안정화시켜 심장과 관련된 사망이나 입원을 감소시킵니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment involves medical therapies and interventions aimed at managing this progressive, life-threatening condition, which is caused by the accumulation of misfolded transthyretin (TTR) proteins in the heart. This buildup leads to restrictive cardiomyopathy and heart failure.

The main treatment types for ATTR-CM include transthyretin stabilizers, nonsteroidal anti-inflammatory drugs (NSAIDs), RNAi therapy, and other treatments. Transthyretin stabilizers work by preventing the misfolding of transthyretin proteins, thereby reducing amyloid deposits and slowing the progression of the disease. Clinical indications for treatment include wild-type ATTR amyloidosis and hereditary ATTR amyloidosis. These treatments are used by various end users, including hospitals, home care settings, specialty clinics, and others.

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market research report is one of a series of new reports from The Business Research Company that provides transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market statistics, including the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment industry global market size, regional shares, competitors with the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market share, detailed transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment industry. This transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market size has grown exponentially in recent years. It will grow from $10.36 billion in 2024 to $13.32 billion in 2025 at a compound annual growth rate (CAGR) of 28.5%. The growth during the historic period can be attributed to the rising prevalence of transthyretin amyloid cardiomyopathy, an increasing occurrence of transthyretin amyloidosis among geriatric patients, greater awareness among healthcare professionals and patients, as well as improvements in healthcare services and overall awareness.

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market size is expected to see exponential growth in the next few years. It will grow to $35.93 billion in 2029 at a compound annual growth rate (CAGR) of 28.2%. The projected growth in the forecast period can be attributed to the increasing prevalence of transthyretin amyloidosis, a rise in the diagnosis of neuropathic disorders, the growing aging population, a higher demand for specific drugs to treat the symptoms of this rare disorder, and an overall increase in healthcare demand. Key trends during this period include the development of new diagnostic technologies, innovative techniques for therapy management, targeted treatments for transthyretin amyloidosis, advancements in diagnostic methods, and improvements in cardiac MRI techniques.

The increasing prevalence of chronic diseases is expected to drive the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in the future. Chronic diseases are long-lasting conditions that progress slowly and can last for a year or more, often requiring ongoing medical care. The rise in chronic diseases is due to factors such as aging populations, sedentary lifestyles, unhealthy diets, rising obesity rates, and exposure to environmental pollutants. Treatment for transthyretin amyloid cardiomyopathy helps stabilize the transthyretin protein, reduce amyloid buildup, improve heart function, and alleviate symptoms, which helps in managing related chronic conditions. For example, in September 2023, the World Health Organization reported that 41 million deaths annually are caused by non-communicable diseases (NCDs) or chronic diseases, accounting for 74% of global deaths. Among these, 17.9 million were due to cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Therefore, the growing prevalence of chronic diseases is fueling the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Companies in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are also focusing on developing innovative treatments, such as oral medications to target and stabilize transthyretin (TTR) proteins or reduce amyloid fibril buildup in the heart. Oral prescription medications are drugs that are taken by mouth, usually in the form of tablets, capsules, or liquid solutions, as prescribed by a healthcare provider. For instance, in November 2024, BridgeBio Pharma Inc., a U.S.-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for Attruby (acoramidis), an oral treatment for adults with transthyretin amyloid cardiomyopathy (ATTR-CM). This medication stabilizes the TTR protein, reducing heart-related deaths and hospitalizations. Clinical trials have demonstrated that it is well-tolerated and provides rapid benefits by targeting the root cause of the disease.

In January 2022, AstraZeneca Plc, a UK-based pharmaceutical company, entered into a partnership with Neurimmune AG, a Switzerland-based biopharmaceutical company. Together, they aim to develop NI006 for the treatment of ATTR-CM, targeting amyloid deposits in the heart. This collaboration seeks to address the growing need for effective treatments for transthyretin amyloid cardiomyopathy (ATTR-CM).

Major players in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG.

North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in transthyretin amyloid cardiomyopathy (ATTR-CM) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The transthyretin amyloid cardiomyopathy (ATTR-CM) market consists of revenues earned by entities by providing services such as diagnosis and screening services, pharmaceutical and drug therapies, patient monitoring and disease management, specialized treatment centers and hospital services. The market value includes the value of related goods sold by the service provider or included within the service offering. The transthyretin amyloid cardiomyopathy (ATTR-CM) market also includes sales of tafamidis, patisiran, vutrisiran, and acoramidis. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on transthyretin amyloid cardiomyopathy (attr-cm) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for transthyretin amyloid cardiomyopathy (attr-cm) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The transthyretin amyloid cardiomyopathy (attr-cm) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Characteristics

3. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Trends And Strategies

4. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Growth Analysis And Strategic Analysis Framework

6. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Segmentation

7. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Regional And Country Analysis

8. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

9. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

10. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

11. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

12. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

13. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

14. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

15. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

16. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

17. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

18. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

19. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

20. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

21. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

22. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

23. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

24. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

25. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

26. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

27. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

28. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

29. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

30. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Landscape And Company Profiles

31. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Other Major And Innovative Companies

32. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

34. Recent Developments In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

35. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기